Infectious diseases now · 2025
Epidemiology and outcomes of multidrug-resistant tuberculosis in Rwanda.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ntwari J, Ndiaye R, Mwiseneza L, Habimana Y, Seruyange E, Sebatunzi O, Migambi P, Rwabihama J P, Gallien S
Аннотация
INTRODUCTION: Multidrug-resistant tuberculosis (MDR-TB) is a significant public health challenge in Rwanda.
METHODS: This retrospective study aimed to describe the epidemiological characteristics, diagnostic approaches, and treatment outcomes of MDR-TB cases between July 1, 2019 and June 30, 2023.
RESULTS: Among 23,476 tuberculosis cases diagnosed in Rwanda, 227 (0.96 %) were confirmed as MDR-TB. Key findings include male predominance (80.6 %) and a mean age of 39.6 years. Pulmonary tuberculosis accounted for 96.9 % of cases, and 20.3 % of patients were co-infected with HIV. The GeneXpert molecular diagnostic test - the first-line diagnostic tool - demonstrated a sensitivity of 92.9 % for detecting resistance to rifampicin and isoniazid. The overall therapeutic success rate was 93.5 %, with a mortality rate of 5.3 % in evaluable cases (82.4 %). Risk factors for mortality included HIV co-infection and malnutrition (BMI < 18.5 kg/m2).
CONCLUSION: These findings underscore the importance of robust diagnostic and treatment strategies to control MDR-TB in Rwanda.
METHODS: This retrospective study aimed to describe the epidemiological characteristics, diagnostic approaches, and treatment outcomes of MDR-TB cases between July 1, 2019 and June 30, 2023.
RESULTS: Among 23,476 tuberculosis cases diagnosed in Rwanda, 227 (0.96 %) were confirmed as MDR-TB. Key findings include male predominance (80.6 %) and a mean age of 39.6 years. Pulmonary tuberculosis accounted for 96.9 % of cases, and 20.3 % of patients were co-infected with HIV. The GeneXpert molecular diagnostic test - the first-line diagnostic tool - demonstrated a sensitivity of 92.9 % for detecting resistance to rifampicin and isoniazid. The overall therapeutic success rate was 93.5 %, with a mortality rate of 5.3 % in evaluable cases (82.4 %). Risk factors for mortality included HIV co-infection and malnutrition (BMI < 18.5 kg/m2).
CONCLUSION: These findings underscore the importance of robust diagnostic and treatment strategies to control MDR-TB in Rwanda.